# Algen Biotechnologies

Source: https://onco.cc/companies/algen-biotechnologies/  
OnCo record `algen-biotechnologies` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Algen uses CRISPR screens read out at the single-cell level, plus machine learning, to find which RNA messages drive cancer and inflammation, and then designs drugs against them.

## Summary

Algen Biotechnologies pairs pooled CRISPR perturbation screens with single-cell RNA readouts and machine learning to identify disease-driving RNA programmes, then pursues first-in-class small molecules and RNA-targeting therapeutics against them for cancer and inflammatory disease. It was founded by a bioengineer from Jennifer Doudna's laboratory with a commercialisation partner. Programmes are discovery stage; no clinical candidates or sourced financing rounds are recorded here.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: South San Francisco, CA
- Type: biotech
- Website: https://www.algenbio.com

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/algen-biotechnologies
- Official website: https://www.algenbio.com

## Connected records

- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [CRISPR functional genomics](https://onco.cc/technologies/crispr-screens/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/algen-biotechnologies.json